🔬Deep Research

AKBA — Akebia Therapeutics Inc · catalysts, narrative & risks

·20 sourcesAKBA forecast →

Overview / Price Context (as of early October 2026)

Akebia Therapeutics (Nasdaq: AKBA) is a Cambridge/Waltham, MA–based fully integrated renal biopharmaceutical company with two FDA-approved products, Vafseo (vadadustat) and Auryxia (ferric citrate) [13], [21], [23]. It is a small-cap name (roughly $255M market cap as of Oct 1, 2026 on file) with a share price that has collapsed: the stock hit $1.29 on the Q2 reporting day (Aug 5) but closed around $0.86 on Oct 2, 2026, versus ~$3.72 a year earlier [7], [11]. That low-price environment is material to the dilution and financing risk profile below.

Recent Catalysts (July–October 2026)


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →